Pay in 4 interest-free payments of $6.53 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Efficacy and safety of liraglutide versus placebo as add-on to glucose-lowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRA-RENAL): A randomized clinical trial
Top lightly if desired
Its also approved to reduce the risk for major cardiovascular events (heart attack, stroke) in adults with type 2 diabetes who also have heart disease
Wegovy (semaglutide): Patients on the 2.4 mg dose lost an average of 15% of their body weight over 68 weeks
And stay GLP-1 wise
19-25 Table 4 provides a summary of key warnings and precautions listed in the labeling of each GLP-1 RA product that should be taken into account when considering use in a patient with T2D
US$ 23.80
US$ 29.39
US$ 21.17
US$ 22.39
US$ 23.89
US$ 23.03
US$ 29.70
